Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Erba

Showing results (81-90 of 162) with videos related to

Pageof 17
Sort By:
British Journal of Haematology|October 14, 2009
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemiaThomas R Chauncey, Holly Gundacker, Mazyar Shadman, et al.
Leukemia Research|January 24, 2019
The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)Bruno C Medeiros, Megan Othus, Martin S Tallman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2003
Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133Patricia A Ganz, Carol M Moinpour, Donna K Pauler, et al.
Leukemia|October 14, 2018
Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trialsMegan Othus, Elihu H Estey, Guillermo Garcia-Manero, et al.
British Journal of Haematology|July 5, 2014
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSSAmer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2014
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapyMegan Othus, Frederick R Appelbaum, Stephen H Petersdorf, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemiaLaura W Dillon, Jake Higgins, Hassan Nasif, et al.
The Journal of Molecular Diagnostics : JMD|July 30, 2023
Genomic Data Heterogeneity across Molecular Diagnostic Laboratories: A Real-World Connect Myeloid Disease Registry Perspective on Variabilities in Genomic Assay Methodology and ReportingJay L Patel, Harry P Erba, Michael R Savona, et al.
British Journal of Haematology|March 4, 2015
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 studyRonan T Swords, Harry P Erba, Daniel J DeAngelo, et al.
European Journal of Endocrinology|October 3, 2001
Retrospective analysis of the association of nodular goiter with primary and secondary hyperparathyroidismL dell'Erba, S Baldari, N Borsato, et al.
Pageof 17

Showing results (81-90 of 162) with videos related to

Sort By:
Pageof 17
British Journal of Haematology|October 14, 2009
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemiaThomas R Chauncey, Holly Gundacker, Mazyar Shadman, et al.
Leukemia Research|January 24, 2019
The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)Bruno C Medeiros, Megan Othus, Martin S Tallman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2003
Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133Patricia A Ganz, Carol M Moinpour, Donna K Pauler, et al.
Leukemia|October 14, 2018
Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trialsMegan Othus, Elihu H Estey, Guillermo Garcia-Manero, et al.
British Journal of Haematology|July 5, 2014
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSSAmer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2014
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapyMegan Othus, Frederick R Appelbaum, Stephen H Petersdorf, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemiaLaura W Dillon, Jake Higgins, Hassan Nasif, et al.
The Journal of Molecular Diagnostics : JMD|July 30, 2023
Genomic Data Heterogeneity across Molecular Diagnostic Laboratories: A Real-World Connect Myeloid Disease Registry Perspective on Variabilities in Genomic Assay Methodology and ReportingJay L Patel, Harry P Erba, Michael R Savona, et al.
British Journal of Haematology|March 4, 2015
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 studyRonan T Swords, Harry P Erba, Daniel J DeAngelo, et al.
European Journal of Endocrinology|October 3, 2001
Retrospective analysis of the association of nodular goiter with primary and secondary hyperparathyroidismL dell'Erba, S Baldari, N Borsato, et al.
Pageof 17